This is a working overview of somatotroph, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-01. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
(R)-MDMA is more potent and efficacious as a serotonin 5-HT2A and 5-HT2B receptor agonist than (S)-MDMA, whereas (S)-MDMA is somewhat more potent as an agonist of the serotonin 5-HT2C receptor. Due to it being a more potent serotonin 5-HT2A receptor agonist than (S)-MDMA, (R)-MDMA has been hypothesized to have greater psychedelic effects than (S)-MDMA or racemic MDMA. However, this proved not to be the case in a direct clinical comparison of (R)-MDMA, (S)-MDMA, and racemic MDMA, with equivalent hallucinogen-like effects instead found between the three interventions. MDMA produces MDA as a minor active metabolite. Peak levels of MDA are about 5 to 10% of those of MDMA and total exposure to MDA is almost 10% of that of MDMA with oral MDMA administration. As a result, MDA may contribute to some extent to the effects of MDMA. MDA is an entactogen, stimulant, and weak psychedelic similarly to MDMA. Like MDMA, it acts as a potent and well-balanced SNDRA and as a weak serotonin 5-HT2 receptor agonist. However, MDA shows much more potent and efficacious serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor agonism than MDMA. Accordingly, MDA produces greater psychedelic effects than MDMA in humans and might particularly contribute to the mild psychedelic-like effects of MDMA. On the other hand, MDA may also be importantly involved in toxicity of MDMA, such as cardiac valvulopathy. The duration of action of MDMA (3–6 hours) is much shorter than its elimination half-life (8–9 hours) would imply.
=== „Große Liebe“ (2014) === After Dein Name with its encompassing, globally oriented poetics came a work of fiction entitled „Große Liebe“ (Love Writ Large), a tightly composed text that is much more homogeneous in terms of language and thematics. The first-person narrator, now in his forties, looks back on his first love, which he felt as a 15-year-old for the slightly older Jutta, a high school student in her senior year. Although the relationship lasted only a few days, its intensity still seems unsurpassed to the narrator decades later. The love story is told in one hundred chapters, which from the outset also reflect on the writing process itself. Over the course of the narrative, it becomes increasingly clear that the narrator is less concerned with his own biography than with the search for a general psycho-physical matrix of first love. He correlates his own experience of love with the teachings on love found in Persian literature, specifically from the tenth to the fourteenth centuries. The narrator reflects on his youthful relationship on the basis of one of the most famous pairs of lovers in Middle Eastern literature, Leila and Majnun, weaving his thoughts together with the reflections on love of the early Islamic mystics. The sacralization of sexuality is already discussed here, as is the comparability of ecstatic loss of self in religion, sexuality, and drug-induced intoxication.
== History == The professional association began as the American Society for Medical Technology (ASMT) and is now known as the American Society for Clinical Laboratory Science (ASCLS). ASMT was organized in 1933 and incorporated in 1936. Early on, members were required to be certified by the Board of Registry (now the Board of Certification) of the American Society of Clinical Pathologists (ASCP) to ensure credibility of the society. During the 1930s, ASMT activities included the inception of a journal, the establishment of a Constitution and Bylaws, the emergence of state charters, and educating the public about the profession. In 1947, ASMT held its first independent convention, compared to earlier national meetings which were held in conjunction with physician groups. During the 1950s, the ASMT Research Fund was established to advance research efforts. In 1962, qualifications for the clinical laboratory scientist (medical technologist) changed to include a baccalaureate degree and a new category of laboratory technician emerged. Also in the 1960s, ASMT joined the International Association of Medical Laboratory Technologists. In the 1970s ASMT grew considerably in numbers (over 30,000 in 1976). The Professional Acknowledgment for Continuing Education (PACE) Program for validating and documenting continuing education was introduced, and the National Accrediting Agency for Clinical Laboratory Sciences (NAACLS) was formed as an independent accreditation agency.
Other efforts to prevent deaths from overdose include increasing access to naloxone and treatment for opioid dependence. Drug use contributes to 500,000 deaths worldwide, with opioid overdose resulting in approximately 115,000 of these deaths in 2018. This is up from 18,000 deaths in 1990. In 2018, approximately 269 million people had engaged in drug usage at least once, 58 million of which used opioids. Drug use disorders have affected around 35.6 million people worldwide in 2018. The WHO estimates that 70% of deaths due to drug use are in relation to opioids, with 30% being due to overdose. It is believed that the opioid epidemic has partly been caused due to assurances that prescription opioids were safe, by the pharmaceutical industry in the 1990s. This led to unwarranted trust and a subsequent heavy reliance on opioids. Though there are treatment interventions which can effectively reduce the risk of overdose in people with opioid dependence, less than 10% of affected individuals receive it.
Sources: en.wikipedia.org
A study skin is a taxidermic zoological specimen prepared in a minimalistic fashion that is concerned only with preserving the animal's skin, not the shape of the animal's body. As the name implies, study skins are used for scientific study (research), and are housed mainly by museums. A study skin's sole purpose is to preserve data, not to replicate an animal in a lifelike state. Museums keep large collections of study skins in order to conduct comparisons of physical characteristics to other study skins of the same species. Study skins are also kept because DNA can be extracted from them when needed at any point in time. A study skin's preparation is extremely basic. After the animal is skinned, fat is methodically scraped off the underside of the hide. The underside of the hide is then rubbed with borax or cedar dust to help it dry faster. The animal is then stuffed with cotton and sewn up. Mammals are laid flat on their belly. Birds are prepared lying on their back. Study skins are dried in these positions to keep the end product as slender and streamlined as possible so large numbers of specimens can be stored side-by-side in flat file drawers, while occupying a minimum amount of space. Since study skins are not prepared with aesthetics in mind they do not have imitation eyes like other taxidermy, and their cotton filling is visible in their eye openings.
=== In plants and in the environment === In plants, L-DOPA functions as an allelochemical which inhibits the growth of certain species, and is produced and secreted by a few legume species such as the broad bean Vicia faba and the velvet bean Mucuna pruriens. Its effect is strongly dependent on the pH and the reactivity of iron in the soil. A 2025 study reported that exogenous L-DOPA triggers a rapid iron-deficiency response in plants, independent of their iron nutritional status. L-DOPA was also suggested to protect Arabidopsis plants against cadmium toxicity. L-DOPA can also be found in cephalopod ink.
=== Memory === It has been found that adrenergic hormones, such as adrenaline, can produce retrograde enhancement of long-term memory in humans. The release of adrenaline due to emotionally stressful events, which is endogenous adrenaline, can modulate memory consolidation of the events, ensuring memory strength that is proportional to memory importance. Post-learning adrenaline activity also interacts with the degree of arousal associated with the initial coding. There is evidence that suggests adrenaline does have a role in long-term stress adaptation and emotional memory encoding specifically. Adrenaline may also play a role in elevating arousal and fear memory under particular pathological conditions, including post-traumatic stress disorder. Overall, "Extensive evidence indicates that epinephrine (EPI) modulates memory consolidation for emotionally arousing tasks in animals and human subjects." Studies have also found that recognition memory involving adrenaline depends on a mechanism that depends on β adrenoceptors. Adrenaline does not readily cross the blood-brain barrier, so its effects on memory consolidation are at least partly initiated by β adrenoceptors in the periphery. Studies have found that sotalol, a β adrenoceptor antagonist that also does not readily enter the brain, blocks the enhancing effects of peripherally administered adrenaline on memory. These findings suggest that β adrenoceptors are necessary for adrenaline to have an impact on memory consolidation.
==== Psychiatric medications ==== Psychiatric medications include antipsychotics and antidepressants that have been shown to lengthen the QT interval and induce TdP, especially when given intravenously or in higher concentrations.
=== T-boxes === These elements are bound by specific uncharged tRNAs and modulate the expression of corresponding aminoacyl-tRNA synthetase operons. High levels of uncharged tRNA promote the anti-terminator sequence leading to increased concentrations of charged tRNA. These are considered by some to be a separate family of riboswitches but are significantly more complex than the previous class of attenuators.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。